SMi Pharma-Masterclass: Genotoxicity
Venue: Central London
|Event Date/Time: Dec 08, 2010||End Date/Time: Dec 08, 2010|
One of the key challenges driving increased productivity in the pharmaceutical industry is the identification of more efficient strategies for reducing attrition rates. Attrition due to Genotoxicity can halt or terminate drug discovery projects and the demonstration of genetic toxicological safety is a regulatory requirement. It is against this backdrop that this masterclass will review the current strategies for early detection of genotoxic chemicals and provide insight into new approaches being adopted for the early identification of Genotoxic hazard. Attendees will learn about new approaches to some existing genotoxicity assays such as the Micronucleus assay as well as reporter based assays such as GreenScreen HC. There will also be a discussion on the anticipated ICH S2(R1) recommendations and the implications for early screening strategies.
About the Masterclass Leader:
Steve Beasley is the Commercial Director at Gentronix. He has over thirty years experience in the pharmaceutical and chemical sector. He trained as an Organic Chemist with Pfizer and Shell Research and gained his D.Phil working with Professor Sir John Cornforth, FRS at the University of Sussex. Steve has managed research teams in Oncology, Inflammation and Immune disorders and was Chief Operating Officer with De Novo Pharmaceuticals responsible for all research and commercial activities. He is a Chartered Chemist and Member of; The Royal Society of Chemistry, Institute of Directors and Institute of Knowledge Transfer.